FEMY FEMASYS INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1339005 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.2%
TTM net income YoY38.7%
TTM EPS YoY175.8%
Revenue 3-yr CAGR21.8%
Net income 3-yr CAGR—
Margins
Gross margin59.9%
Operating margin-929.9%
Net margin-614.7%
FCF margin-877.5%
EBITDA margin-913.3%
Returns
ROE-76.9%
ROA-47.3%
ROIC (approx.)-935.4%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets23.0%
Debt / equity0.00x
Current ratio8.67x
Interest coverage-18.91x
Cash quality & payout
Operating cash flow / net income1.41x
Accruals ratio19.2%
Payout ratio—
Capex / revenue12.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $404,597 | $331,827 | $424,889 | $813,387 | $729,394 | $409,268 | $341,264 | $581,576 |
| Cost of revenue | $187,496 | $142,436 | $158,606 | $303,125 | $293,838 | $158,171 | $117,266 | $192,407 |
| Gross profit | $217,101 | $189,391 | $266,283 | $510,262 | $435,556 | $251,097 | $223,998 | $389,169 |
| R&D expense | $1.94M | $1.95M | $1.31M | $1.81M | $1.38M | $1.41M | $2.97M | $2.17M |
| SG&A expense | $1.70M | $1.93M | $1.78M | $1.83M | $1.48M | $1.62M | $1.72M | $1.68M |
| Operating income | -$4.45M | -$5.07M | -$4.22M | -$4.62M | -$3.65M | -$3.85M | -$5.46M | -$4.72M |
| Interest expense | $200,415 | $186,050 | $176,607 | $408,097 | $532,073 | $491,500 | $459,449 | $440,422 |
| Pretax income | -$4.56M | -$4.47M | $846,100 | -$3.94M | -$4.19M | -$4.59M | -$5.90M | -$5.11M |
| Income tax | $0 | $865 | $0 | $5,485 | $0 | $0 | -$4,188 | $10,194 |
| Net income | -$4.56M | -$4.47M | $846,100 | -$3.95M | -$4.19M | -$4.59M | -$5.90M | -$5.12M |
| EBITDA | -$4.37M | -$4.98M | -$4.14M | -$4.54M | -$3.57M | -$3.77M | -$5.38M | -$4.64M |
| EPS (basic) | -0.53 | -1.33 | 0.00 | — | -2.05 | -3.18 | -0.23 | — |
| EPS (diluted) | -0.53 | -1.33 | 0.00 | — | -2.05 | -3.18 | -0.23 | — |
| Weighted avg. shares (diluted) | 8.66M | 3.36M | 78.10M | — | 2.05M | 1.44M | 25.15M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $23.91M | $1.44M | $5.39M | $9.27M | $4.57M | $3.22M | $3.82M | $3.45M |
| Receivables | $233,778 | $151,049 | $172,264 | $616,600 | $572,199 | $254,584 | $233,598 | $488,373 |
| Inventory | $6.17M | $6.19M | $6.11M | $5.74M | $5.78M | $5.23M | $3.86M | $3.05M |
| Current assets | $31.21M | $8.33M | $12.34M | $16.46M | $12.25M | $9.75M | $9.13M | $8.02M |
| PP&E, net | $1.88M | $1.86M | $1.92M | $1.90M | $1.75M | $1.60M | $1.58M | $1.60M |
| Intangibles | $99,902 | $115,499 | $124,252 | $134,914 | $130,041 | $55,638 | $58,747 | $65,918 |
| Total assets | $35.09M | $12.29M | $16.50M | $20.72M | $16.29M | $13.78M | $13.28M | $12.45M |
| Current liabilities | $3.60M | $3.89M | $3.16M | $3.64M | $10.54M | $10.96M | $9.84M | $8.58M |
| Total liabilities | $8.06M | $8.26M | $9.21M | $14.85M | $11.73M | $12.27M | $11.28M | $10.14M |
| Shareholders' equity | $27.03M | $4.03M | $7.29M | $5.87M | $4.56M | $1.51M | $2.00M | $2.30M |
| Shares outstanding | 8.66M | 3.02M | 60.39M | 2.98M | 47.30M | 32.58M | 27.09M | 23.36M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.82M | -$3.94M | -$4.14M | -$4.19M | -$5.39M | -$4.35M | -$4.77M | -$5.07M |
| Capital expenditure | $17,510 | $9,402 | $79,138 | $139,840 | $194,333 | $94,229 | $96,605 | $106,792 |
| Free cash flow | -$4.84M | -$3.95M | -$4.22M | -$4.33M | -$5.58M | -$4.45M | -$4.86M | -$5.18M |
| Investing cash flow | -$21,015 | -$22,179 | -$79,138 | -$196,715 | -$239,816 | -$96,962 | -$96,605 | -$110,613 |
| Financing cash flow | $27.31M | $15,329 | $342,334 | $9.08M | $6.98M | $3.85M | $5.23M | $1.03M |
| Depreciation & amortization | $77,091 | $82,811 | $82,270 | $85,199 | $85,697 | $86,285 | $84,853 | $82,174 |
| Stock-based compensation | $190,216 | $210,820 | $151,608 | $66,423 | $174,514 | $181,971 | $367,237 | $134,143 |
| Share buybacks | — | — | — | — | — | — | $161,761 | $30,093 |
Free plan shows the latest 8 periods; Pro shows all 26 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.